Mustang Bio, Inc. (NASDAQ:MBIO) shares appear to be trending upward Tuesday on continued momentum after the company on Monday announced safety and efficacy data from its Phase 1/2 clinical trial of MB-106, a possible treatment for certain types of blood cancer.

90% of patients treated with MB-106 responded to the treatment with three complete responses. Out of the three complete responses, one of the participants remains in complete remission at 31 months.

Mustang Bio is developing the treatment in collaboration with Fred Hutch Cancer Center. The data was presented at the European Hematology Association 2024 Hybrid Congress.

MBIO Price Action: Mustang Bio stock is trading 35.9% higher at 99 cents at the time of writing, according to data from Benzinga Pro.

Image: Emilian Danaila from Pixabay